Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinosito

Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

The glycomic therapeutics market in Asia Pacific is expected to grow from US$ 12,950.82 million in 2022 to US$ 34,592.83 million by 2028; it is estimated to grow at a CAGR of 17.8% from 2022 to 2028.

Wide Applications of Glycomics in Therapeutics to Provide Lucrative Opportunities for Market Growth

Glycomics is a novel method for creating medicines. It draws on the knowledge that glycans serve as the primary means of altering numerous molecules in biological systems. This alteration provides those molecules with their complete, functional form. Glycans are found in most top-selling biologics and half of the therapeutic proteins, including antibodies against COVID-19. Glycans of these proteins have been tailored to improve their effectiveness, lower the dosages required, and lessen negative effects. For instance, understanding the biological functions of glycans has led to their inclusion as essential ingredients in medications for the treatment of diabetes, the prevention of blood clotting, and the improvement of in vitro fertilization. Changes in the glycans on a microbe's surface are frequently connected to the microorganisms' resistance to popular medications. This property is used for detecting particular glycans in infection samples, disabling the protective biofilms formed by the infecting bacteria, and weakening the glycan-rich cell walls of microorganisms. More than 130 uncommon genetic illnesses, many of which are fatal in childhood, are brought on by errors. Understanding the glycans responsible for a few of these problems has helped develop therapies. Since glycans can play a crucial role in studying attacks of bacteria and viruses on the immune systems of humans, they are employed in vaccinations. Additionally, recent research on SARS-CoV-2, which causes COVID-19, has shown infection pathways that depend on the virus's usage of human glycans. Glycomics has the potential to bring new perspectives to precision medicine, which is currently dominated by genetic and proteomic tools. Therefore, the high adoption of glycomics in various therapeutic areas would propel the demand for these techniques in the coming years. Nonetheless, ongoing research and developments and clinical advancements in the field of therapeutics are expected to create lucrative growth opportunities for the glycomics therapeutics market during the forecast period.

Market Overview



Asia Pacific (APAC) is the fastest-growing market for glycomic therapeutics. The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is likely to account for ~11.89% share of the global glycomic therapeutics market in 2022 owing to the improving government support in countries, collaboration of research organizations, rising glycomics research institutes, and advancing healthcare infrastructure. Therefore, the region offers several opportunities for the glycomic therapeutics market players to grow during the forecast period.

Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

Asia Pacific Glycomic Therapeutics Market Segmentation

The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Asia Pacific glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Asia Pacific glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Asia Pacific glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Asia Pacific glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; Alzheon, Inc.; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics market in Asia Pacific.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Glycomic Therapeutics Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.